Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 156 articles:
HTML format

Single Articles

    June 2021
  1. AHN BC, So JW, Synn CB, Kim TH, et al
    Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
    Eur J Cancer. 2021;153:179-189.
    PubMed     Abstract available

  2. CANTINI L, Pecci F, Dammeijer F, Aerts JGJV, et al
    Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Eur J Cancer. 2021 Jun 18. pii: S0959-8049(21)00325.

    May 2021
  3. HARA A, Matsuda M, Ishii A, Yoshioka T, et al
    Comments on 'High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'.
    Eur J Cancer. 2021 May 22. pii: S0959-8049(21)00256.

  4. BOGATYROVA O, Mattsson JSM, Ross EM, Sanderson MP, et al
    FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
    Eur J Cancer. 2021;151:136-149.
    PubMed     Abstract available

  5. IKEDA S, Kato T, Kenmotsu H, Okamoto H, et al
    Immune checkpoint inhibitor for non-small cell lung cancer with comorbid interstitial pneumonia; a prudent stance required.
    Eur J Cancer. 2021 May 4. pii: S0959-8049(21)00217.

  6. DUCHEMANN B, Pluvy J, Crestani B, Zalcman G, et al
    Immune checkpoint inhibitors for patients with lung cancer and IPF: Specific clinical trials needed.
    Eur J Cancer. 2021 May 4. pii: S0959-8049(21)00219.

  7. ROGADO J, Gullon P, Obispo B, Serrano G, et al
    Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
    Eur J Cancer. 2021;148:58-60.

    April 2021
  8. BUTI S, Bersanelli M, Perrone F, Bracarda S, et al
    Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
    Eur J Cancer. 2021;150:224-231.
    PubMed     Abstract available

  9. DALL'OLIO FG, Calabro D, Conci N, Argalia G, et al
    Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab.
    Eur J Cancer. 2021;150:99-107.
    PubMed     Abstract available

  10. FUJIMOTO D, Miura S, Yoshimura K, Wakuda K, et al
    Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naive patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
    Eur J Cancer. 2021;150:63-72.
    PubMed     Abstract available

  11. ZHENG MM, Tu HY, Yang JJ, Zhang XC, et al
    Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Eur J Cancer. 2021;150:23-30.
    PubMed     Abstract available

  12. JACOBS F, Carnio S, De Stefanis P, Luciano A, et al
    Pericarditis during chemoimmunotherapy for non-small cell lung cancer: an adverse event to prevent and recognise.
    Eur J Cancer. 2021;149:114-116.

  13. OCHI N, Ichihara E, Takigawa N, Harada D, et al
    The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Eur J Cancer. 2021;149:73-81.
    PubMed     Abstract available

  14. PROVENCIO M, Serna-Blasco R, Franco F, Calvo V, et al
    Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
    Eur J Cancer. 2021;149:61-72.
    PubMed     Abstract available

  15. TANAKA K, Asahina H, Kishimoto J, Miyata Y, et al
    Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Eur J Cancer. 2021;149:14-22.
    PubMed     Abstract available

    March 2021
  16. LEE K, Kim D, Yoon S, Lee DH, et al
    Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Eur J Cancer. 2021;148:202-210.
    PubMed     Abstract available

  17. SCHOTTEN LM, Darwiche K, Seweryn M, Yildiz V, et al
    DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
    Eur J Cancer. 2021;147:142-150.
    PubMed     Abstract available

    February 2021
  18. THOMPSON LL, Nadelmann ER, Blum AE, Yoon J, et al
    Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer.
    Eur J Cancer. 2021;147:13-16.

    January 2021
  19. GATAA I, Mezquita L, Rossoni C, Auclin E, et al
    Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Eur J Cancer. 2021;145:221-229.
    PubMed     Abstract available

  20. ITO K, Yamanaka T, Hayashi H, Hattori Y, et al
    Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study.
    Eur J Cancer. 2021;145:183-193.
    PubMed     Abstract available

  21. DUCHEMANN B, Pluvy J, Crestani B, Zalcman G, et al
    Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
    Eur J Cancer. 2021;145:179-182.

  22. SORIAL MN, Huynh JP, Azzoli CG, Liauw JC, et al
    Survival outcomes associated with corticosteroid use before chemoimmunotherapy in patients with advanced lung cancer.
    Eur J Cancer. 2021 Jan 8. pii: S0959-8049(20)31427.
    PubMed     Abstract available

  23. SKRIBEK M, Rounis K, Afshar S, Grundberg O, et al
    Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Eur J Cancer. 2021 Jan 5. pii: S0959-8049(20)31428.
    PubMed     Abstract available

  24. REINMUTH N, Schuler M
    Shall we use steroids when treating patients with lung cancer with checkpoint inhibitors?
    Eur J Cancer. 2021 Jan 5. pii: S0959-8049(20)31429.

  25. BUTI S, Bersanelli M, Perrone F, Tiseo M, et al
    Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Eur J Cancer. 2021;142:18-28.
    PubMed     Abstract available

    December 2020
  26. JIA J, Guo B, Yang Z, Liu Y, et al
    Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: A SEER-based analysis.
    Eur J Cancer. 2020;144:326-340.
    PubMed     Abstract available

  27. YOSHIDA H, Nomizo T, Ozasa H, Tsuji T, et al
    PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
    Eur J Cancer. 2020;144:317-325.
    PubMed     Abstract available

  28. CANTINI L, Pecci F, Hurkmans DP, Belderbos RA, et al
    High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
    Eur J Cancer. 2020;144:41-48.
    PubMed     Abstract available

  29. TABBO F, Guerrera F, van den Berg A, Gaudiano M, et al
    Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.
    Eur J Cancer. 2020;144:17-30.
    PubMed     Abstract available

  30. KIM CG, Hong MH, Kim KH, Seo IH, et al
    Dynamic changes in circulating PD-1(+)CD8(+) T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer.
    Eur J Cancer. 2020;143:113-126.
    PubMed     Abstract available

  31. KASHIZAKI F, Tanaka A, Hattori S, Sugimoto S, et al
    Dabrafenib-trametinib combination therapy re-challenge in advanced BRAF(V600E)-mutant non-small-cell lung cancer.
    Eur J Cancer. 2020;143:31-32.

  32. MAZZARELLA L, Giugliano S, D'Amico P, Belli C, et al
    Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity.
    Eur J Cancer. 2020;141:218-224.
    PubMed     Abstract available

    November 2020
  33. DESILETS A, Blanc-Durand F, Lau S, Hakozaki T, et al
    Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
    Eur J Cancer. 2020;142:83-91.
    PubMed     Abstract available

  34. PENG X, Long X, Liu L, Zeng L, et al
    Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Eur J Cancer. 2020;141:199-208.
    PubMed     Abstract available

  35. MUNOZ-UNCETA N, Zugazagoitia J, Manzano A, Jimenez-Aguilar E, et al
    High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
    Eur J Cancer. 2020;141:193-198.
    PubMed     Abstract available

  36. ORBACH D, Andre N, Brecht IB, Lopez Almaraz R, et al
    Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution.
    Eur J Cancer. 2020;140:63-70.
    PubMed     Abstract available

    October 2020
  37. WIESWEG M, Mairinger F, Reis H, Goetz M, et al
    Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Eur J Cancer. 2020;140:76-85.
    PubMed     Abstract available

  38. TAI YH, Wu HL, Mandell MS, Lin SP, et al
    The association of non-small cell lung cancer recurrence with allogenic blood transfusion after surgical resection: A propensity score analysis of 1,803 patients.
    Eur J Cancer. 2020;140:45-54.
    PubMed     Abstract available

  39. SHIRASAWA M, Yoshida T, Matsumoto Y, Shinno Y, et al
    Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Eur J Cancer. 2020;140:28-36.
    PubMed     Abstract available

    September 2020
  40. QUOIX E, Audigier-Valette C, Lavole A, Molinier O, et al
    Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.
    Eur J Cancer. 2020;138:193-201.
    PubMed     Abstract available

  41. GUBERINA N, Pottgen C, Schuler M, Guberina M, et al
    Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve.
    Eur J Cancer. 2020;138:156-168.
    PubMed     Abstract available

    August 2020
  42. YANES M, Santoni G, Maret-Ouda J, Ness-Jensen E, et al
    Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study.
    Eur J Cancer. 2020;138:80-88.
    PubMed     Abstract available

  43. BANG YJ, Golan T, Dahan L, Fu S, et al
    Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Eur J Cancer. 2020;137:272-284.
    PubMed     Abstract available

  44. MONTRONE M, Catino A, Palmieri VO, Longo V, et al
    Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
    Eur J Cancer. 2020;138:109-112.

    July 2020
  45. PASSIGLIA F, Malapelle U, Del Re M, Righi L, et al
    KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.
    Eur J Cancer. 2020;137:57-68.
    PubMed     Abstract available

  46. MANKOR JM, Zwierenga F, Dumoulin DW, Neefjes JJC, et al
    A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?
    Eur J Cancer. 2020;137:40-44.
    PubMed     Abstract available

  47. TSUKITA Y, Miyauchi E, Fukudo M, Sasaki T, et al
    Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab.
    Eur J Cancer. 2020;133:22-24.

    June 2020
  48. BOULLE G, Velut Y, Mansuet-Lupo A, Gibault L, et al
    Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
    Eur J Cancer. 2020;135:221-229.
    PubMed     Abstract available

  49. DU Y, Sidorenkov G, Heuvelmans MA, Groen HJM, et al
    Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
    Eur J Cancer. 2020;135:121-129.
    PubMed     Abstract available

  50. SADATE A, Occean BV, Beregi JP, Hamard A, et al
    Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography.
    Eur J Cancer. 2020;134:107-114.
    PubMed     Abstract available

  51. LEE J, Choi Y, Jung HA, Lee SH, et al
    Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
    Eur J Cancer. 2020;132:150-158.
    PubMed     Abstract available

  52. TORRICELLI F, Saxena A, Nuamah R, Neat M, et al
    Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
    Eur J Cancer. 2020;132:104-111.
    PubMed     Abstract available

  53. TOMOAIA R, Beyer RS, Pop D, Minciuna IA, et al
    Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
    Eur J Cancer. 2020;132:224-227.

    May 2020
  54. YIM J, Koh J, Kim S, Song SG, et al
    Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
    Eur J Cancer. 2020;133:74-85.
    PubMed     Abstract available

  55. FACCHINETTI F, Lacroix L, Mezquita L, Scoazec JY, et al
    Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF(V600E) non-small cell lung cancer.
    Eur J Cancer. 2020;132:211-223.
    PubMed     Abstract available

  56. PAGE S, Milner-Watts C, Perna M, Janzic U, et al
    Systemic treatment of brain metastases in non-small cell lung cancer.
    Eur J Cancer. 2020;132:187-198.
    PubMed     Abstract available

  57. CHORTI E, Kanaki T, Zimmer L, Hadaschik E, et al
    Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Eur J Cancer. 2020;131:18-26.
    PubMed     Abstract available

    April 2020
  58. LEONETTI A, Facchinetti F, Zielli T, Brianti E, et al
    COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors.
    Eur J Cancer. 2020;132:122-124.

  59. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    PubMed     Abstract available

  60. CORTOT AB, Audigier-Valette C, Molinier O, Le Moulec S, et al
    Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
    Eur J Cancer. 2020;131:27-36.
    PubMed     Abstract available

  61. TU L, Liu J, Li Z, Liu Y, et al
    Early detection and management of immune-related myocarditis: Experience from a case with advanced squamous cell lung carcinoma.
    Eur J Cancer. 2020;131:5-8.

    March 2020
  62. FACCHINETTI F, Mazzaschi G, Barbieri F, Passiglia F, et al
    First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
    Eur J Cancer. 2020;130:155-167.
    PubMed     Abstract available

  63. LEE PH, Lee TY, Chang GC
    Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection.
    Eur J Cancer. 2020 Mar 20. pii: S0959-8049(20)30099.

  64. BOUDOU-ROUQUETTE P, Grignano E, Arrondeau J, Burroni B, et al
    Diffuse large B-cell lymphoma after nivolumab treatment for lung cancer: A case report and a World Health Organization pharmacovigilance database review.
    Eur J Cancer. 2020;130:20-22.

  65. MARQUES JF, Junqueira-Neto S, Pinheiro J, Machado JC, et al
    Induction of apoptosis increases sensitivity to detect cancer mutations in plasma.
    Eur J Cancer. 2020;127:130-138.
    PubMed     Abstract available

  66. NI J, Zhang L, Zhang X
    Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy.
    Eur J Cancer. 2020;128:57-59.

    February 2020
  67. FELIP E, Ardizzoni A, Ciuleanu T, Cobo M, et al
    CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
    Eur J Cancer. 2020;127:160-172.
    PubMed     Abstract available

  68. SAITO S, Kadota T, Gochi M, Takagi M, et al
    Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome.
    Eur J Cancer. 2020;126:74-77.

    January 2020
  69. CONFORTI F, Pala L, Pagan E, Bagnardi V, et al
    Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.
    Eur J Cancer. 2020;125:94-103.
    PubMed     Abstract available

  70. YANG CY, Liao WY, Ho CC, Chen KY, et al
    Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Eur J Cancer. 2020;124:110-122.
    PubMed     Abstract available

    December 2019
  71. LEIGHL NB, Karaseva N, Nakagawa K, Cho BC, et al
    Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.
    Eur J Cancer. 2019;125:49-57.
    PubMed     Abstract available

  72. CALIFANO R, Gomes F, Ackermann CJ, Rafee S, et al
    Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
    Eur J Cancer. 2019;125:1-11.
    PubMed     Abstract available

    November 2019
  73. WANG S, Ma P, Ma G, Lv Z, et al
    Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
    Eur J Cancer. 2019;124:1-14.
    PubMed     Abstract available

  74. DUCREUX M, Petersen LN, Ohler L, Bergamo F, et al
    Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study.
    Eur J Cancer. 2019;123:146-154.
    PubMed     Abstract available

    October 2019
  75. LEVY A, Hendriks LEL, Berghmans T, Faivre-Finn C, et al
    EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease.
    Eur J Cancer. 2019;122:109-114.
    PubMed     Abstract available

  76. GROSSI F, Genova C, Crino L, Delmonte A, et al
    Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Eur J Cancer. 2019;123:72-80.
    PubMed     Abstract available

  77. HENDRIKS LEL, Dooms C, Berghmans T, Novello S, et al
    Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion.
    Eur J Cancer. 2019;123:28-35.
    PubMed     Abstract available

  78. CHOI WI, Jeong J, Lee CW
    Association between EGFR mutation and ageing, history of pneumonia and gastroesophageal reflux disease among patients with advanced lung cancer.
    Eur J Cancer. 2019;122:101-108.
    PubMed     Abstract available

  79. ABDEL-AZIZ AK, Saadeldin MK, D'Amico P, Orecchioni S, et al
    Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
    Eur J Cancer. 2019;122:22-41.
    PubMed     Abstract available

    September 2019
  80. JIANG T, Zhang Y, Li X, Zhao C, et al
    EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
    Eur J Cancer. 2019;121:98-108.
    PubMed     Abstract available

  81. VISSER S, Koolen SLW, de Bruijn P, Belderbos HNA, et al
    Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study.
    Eur J Cancer. 2019;121:64-73.
    PubMed     Abstract available

  82. DE JONG EEC, Sanders KJC, Deist TM, van Elmpt W, et al
    Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?
    Eur J Cancer. 2019;120:107-113.
    PubMed     Abstract available

  83. LEE SM, Upadhyay S, Lewanski C, Falk S, et al
    The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
    Eur J Cancer. 2019;120:86-96.
    PubMed     Abstract available

    August 2019
  84. YUAN P, Huang S, Bao FC, Cao JL, et al
    Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Eur J Cancer. 2019;120:10-19.
    PubMed     Abstract available

  85. MAK DWS, Li S, Minchom A
    Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Eur J Cancer. 2019;119:132-150.
    PubMed     Abstract available

  86. CHANG LC, Lim CK, Chang LY, Chen KY, et al
    Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Eur J Cancer. 2019;119:77-86.
    PubMed     Abstract available

  87. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Eur J Cancer. 2019;117:107-115.
    PubMed     Abstract available

    July 2019
  88. PASTORINO U, Sverzellati N, Sestini S, Silva M, et al
    Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening.
    Eur J Cancer. 2019;118:142-148.
    PubMed     Abstract available

  89. GEZELIUS E, Bendahl PO, Goncalves de Oliveira K, Ek L, et al
    Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
    Eur J Cancer. 2019;118:82-90.
    PubMed     Abstract available

  90. ARFFMAN M, Manderbacka K, Suvisaari J, Koivunen J, et al
    The impact of severe mental illness on lung cancer mortality of patients with lung cancer in Finland in 1990-2013: a register-based cohort study.
    Eur J Cancer. 2019;118:105-111.
    PubMed     Abstract available

    June 2019
  91. LINDSAY CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, et al
    EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Eur J Cancer. 2019;117:60-68.
    PubMed     Abstract available

  92. HENDRIKS LEL, Bootsma G, Mourlanette J, Henon C, et al
    Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Eur J Cancer. 2019;116:182-189.
    PubMed     Abstract available

  93. RECK M, Schenker M, Lee KH, Provencio M, et al
    Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
    Eur J Cancer. 2019;116:137-147.
    PubMed     Abstract available

  94. COURAUD S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, et al
    Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Eur J Cancer. 2019;116:86-97.
    PubMed     Abstract available

    May 2019
  95. FOUCHARD M, Jantzem H, Quere G, Descourt R, et al
    Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Eur J Cancer. 2019;115:107-110.

  96. SCHOENMAEKERS J, Hofman P, Bootsma G, Westenend M, et al
    Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
    Eur J Cancer. 2019;115:88-96.
    PubMed     Abstract available

    April 2019
  97. MCGOWAN DR, Skwarski M, Bradley KM, Campo L, et al
    Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    Eur J Cancer. 2019;113:87-95.
    PubMed     Abstract available

    February 2019
  98. RATHOD S, Jeremic B, Dubey A, Giuliani M, et al
    Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials.
    Eur J Cancer. 2019;110:110-119.
    PubMed     Abstract available

  99. WANG Z, Huang C, Yang JJ, Song Y, et al
    A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
    Eur J Cancer. 2019;109:183-191.
    PubMed     Abstract available

    January 2019
  100. LEVY BP, Giaccone G, Besse B, Felip E, et al
    Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Eur J Cancer. 2019;108:120-128.
    PubMed     Abstract available

  101. BASAK EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, et al
    Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Eur J Cancer. 2019;109:12-20.
    PubMed     Abstract available

  102. CHARRIER M, Mezquita L, Lueza B, Dupraz L, et al
    Circulating innate immune markers and outcomes in treatment-naive advanced non-small cell lung cancer patients.
    Eur J Cancer. 2019;108:88-96.
    PubMed     Abstract available

    December 2018
  103. SCHWARTZ S, Szeto C, Tian Y, Cecchi F, et al
    Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase.
    Eur J Cancer. 2018;107:164-174.
    PubMed     Abstract available

  104. VON PAWEL J, Bordoni R, Satouchi M, Fehrenbacher L, et al
    Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
    Eur J Cancer. 2018;107:124-132.
    PubMed     Abstract available

  105. PRELAJ A, Tay R, Ferrara R, Chaput N, et al
    Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
    Eur J Cancer. 2018;106:144-159.
    PubMed     Abstract available

    November 2018
  106. IMANISHI M, Yamamoto Y, Hamano Y, Yamada T, et al
    Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity score-matched analysis.
    Eur J Cancer. 2018;106:69-77.
    PubMed     Abstract available

    October 2018
  107. WIJN DH, Groeneveld GH, Vollaard AM, Muller M, et al
    Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Eur J Cancer. 2018;104:182-187.
    PubMed     Abstract available

    September 2018
  108. JONES GS, McKeever TM, Hubbard RB, Khakwani A, et al
    Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data.
    Eur J Cancer. 2018;103:176-183.
    PubMed     Abstract available

    August 2018
  109. RECK M, Brahmer J, Bennett B, Taylor F, et al
    Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Eur J Cancer. 2018;102:23-30.
    PubMed     Abstract available

  110. HORN L, Gettinger SN, Gordon MS, Herbst RS, et al
    Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
    Eur J Cancer. 2018;101:201-209.
    PubMed     Abstract available

  111. BONANNO L, Pavan A, Dieci MV, Di Liso E, et al
    The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
    Eur J Cancer. 2018;101:191-200.
    PubMed     Abstract available

  112. GANTENBEIN N, Bernhart E, Anders I, Golob-Schwarzl N, et al
    Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
    Eur J Cancer. 2018;101:165-180.
    PubMed     Abstract available

    July 2018
  113. LIU SV, Camidge DR, Gettinger SN, Giaccone G, et al
    Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Eur J Cancer. 2018;101:114-122.
    PubMed     Abstract available

  114. DETILLON DDEMA, Driessen EJM, Aarts MJ, Janssen-Heijnen MLG, et al
    Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery.
    Eur J Cancer. 2018;101:30-37.
    PubMed     Abstract available

  115. GROSSI F, Crino L, Logroscino A, Canova S, et al
    Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Eur J Cancer. 2018;100:126-134.
    PubMed     Abstract available

    June 2018
  116. LINDSAY CR, Jamal-Hanjani M, Forster M, Blackhall F, et al
    KRAS: Reasons for optimism in lung cancer.
    Eur J Cancer. 2018;99:20-27.
    PubMed     Abstract available

    May 2018
  117. TAKENAKA T, Kawai Y, Amano T
    Immune checkpoint therapy in proteinuric kidney disease.
    Eur J Cancer. 2018;95:120-122.

    April 2018
  118. PRADERE P, Boutros C, Scoazec JY, Dorfmuller P, et al
    Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
    Eur J Cancer. 2018;93:144-146.

    March 2018
  119. DALL'OLIO FG, Brocchi S, Massucci M, Sperandi F, et al
    Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?
    Eur J Cancer. 2018 Mar 21. pii: S0959-8049(18)30227.

  120. SCHIEFER M, Hendriks LEL, Dinh T, Lalji U, et al
    Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
    Eur J Cancer. 2018;91:92-98.
    PubMed     Abstract available

    February 2018
  121. LEVY A, Faivre-Finn C, Hasan B, De Maio E, et al
    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
    Eur J Cancer. 2018;93:37-46.
    PubMed     Abstract available

    January 2018
  122. SNEE M
    Quality of life comparing carboplatin with cisplatin in the treatment of non-small cell lung cancer.
    Eur J Cancer. 2018 Jan 2. pii: S0959-8049(17)31427.

  123. TAZDAIT M, Mezquita L, Lahmar J, Ferrara R, et al
    Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
    Eur J Cancer. 2018;88:38-47.
    PubMed     Abstract available

    December 2017
  124. ANGEVIN E, Spitaleri G, Rodon J, Dotti K, et al
    A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Eur J Cancer. 2017;87:131-139.
    PubMed     Abstract available

    November 2017
  125. KINOSHITA T, Kudo-Saito C, Muramatsu R, Fujita T, et al
    Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Eur J Cancer. 2017;86:15-27.
    PubMed     Abstract available

    October 2017
  126. IIJIMA Y, Hirotsu Y, Amemiya K, Ooka Y, et al
    Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Eur J Cancer. 2017;86:349-357.
    PubMed     Abstract available

  127. SORIA JC, Adjei AA, Bahleda R, Besse B, et al
    A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced n
    Eur J Cancer. 2017;86:186-196.
    PubMed     Abstract available

  128. DE LA PENA H, Sharma A, Glicksman C, Joseph J, et al
    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
    Eur J Cancer. 2017;84:354-359.
    PubMed     Abstract available

  129. SHI Y, Lin P, Ho EY, Nock CJ, et al
    Nivolumab-associated nausea and vomiting as an immune adverse event.
    Eur J Cancer. 2017;84:367-369.

    September 2017
  130. MAHJOUBI L, Gazzah A, Marabelle A, Le Roy Ladurie F, et al
    Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
    Eur J Cancer. 2017 Sep 13. pii: S0959-8049(17)31197.

  131. MCWILLIAM A, Kennedy J, Hodgson C, Vasquez Osorio E, et al
    Radiation dose to heart base linked with poorer survival in lung cancer patients.
    Eur J Cancer. 2017;85:106-113.
    PubMed     Abstract available

  132. LIN PL, Wu TC, Wu DW, Wang L, et al
    An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Eur J Cancer. 2017;85:95-105.
    PubMed     Abstract available

    August 2017
  133. LI F, Zhu T, Cao B, Wang J, et al
    Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Eur J Cancer. 2017;84:184-192.
    PubMed     Abstract available

  134. JIANG T, Ren S, Li X, Su C, et al
    The changing diagnostic pathway for lung cancer patients in Shanghai, China.
    Eur J Cancer. 2017;84:168-172.
    PubMed     Abstract available

  135. CUFARI ME, Proli C, De Sousa P, Raubenheimer H, et al
    Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK.
    Eur J Cancer. 2017;84:55-59.
    PubMed     Abstract available

  136. FERRY D, Billingham L, Jarrett H, Dunlop D, et al
    Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
    Eur J Cancer. 2017;83:302-312.
    PubMed     Abstract available

    July 2017
  137. SU C, Zhou F, Shen J, Zhao J, et al
    Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challen
    Eur J Cancer. 2017;83:266-278.
    PubMed     Abstract available

  138. SABRKHANY S, Kuijpers MJE, van Kuijk SMJ, Sanders L, et al
    A combination of platelet features allows detection of early-stage cancer.
    Eur J Cancer. 2017;80:5-13.
    PubMed     Abstract available

  139. MICHOT JM, Vargaftig J, Leduc C, Quere G, et al
    Immune-related bone marrow failure following anti-PD1 therapy.
    Eur J Cancer. 2017;80:1-4.

    June 2017
  140. GANDHI L, Ignatius Ou SH, Shaw AT, Barlesi F, et al
    Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Eur J Cancer. 2017;82:27-33.
    PubMed     Abstract available

  141. BERNABE R, Hickson N, Wallace A, Blackhall FH, et al
    What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Eur J Cancer. 2017;81:66-73.
    PubMed     Abstract available

  142. DEVIC P, Amini-Adle M, Camdessanche JP, Dalle S, et al
    Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Eur J Cancer. 2017;78:103-104.

    May 2017
  143. BRIGHENTI M, Petrelli F, Barni S, Conti B, et al
    Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
    Eur J Cancer. 2017;79:149-151.
    PubMed     Abstract available

  144. PASTORINO U, Morelli D, Leuzzi G, Gisabella M, et al
    Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer.
    Eur J Cancer. 2017;79:90-97.
    PubMed     Abstract available

  145. DE JONGE M, de Weger VA, Dickson MA, Langenberg M, et al
    A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    Eur J Cancer. 2017;76:144-151.
    PubMed     Abstract available

  146. PALMERINI E, Chawla NS, Ferrari S, Sudan M, et al
    Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Eur J Cancer. 2017;76:118-124.
    PubMed     Abstract available

  147. RAVAUD A, de la Fouchardiere C, Caron P, Doussau A, et al
    A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Eur J Cancer. 2017;76:110-117.
    PubMed     Abstract available

  148. ZSCHABITZ S, Lasitschka F, Hadaschik B, Hofheinz RD, et al
    Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Eur J Cancer. 2017;76:1-7.
    PubMed     Abstract available

    April 2017
  149. GIROUX LEPRIEUR E, Dumenil C, Julie C, Giraud V, et al
    Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Eur J Cancer. 2017;78:16-23.
    PubMed     Abstract available

  150. SULLIVAN I, Le Teuff G, Guigay J, Caramella C, et al
    Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Eur J Cancer. 2017;75:259-267.
    PubMed     Abstract available

  151. KIM S, Koh J, Kwon D, Keam B, et al
    Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
    Eur J Cancer. 2017;75:141-149.
    PubMed     Abstract available

  152. PRADERE P, Michot JM, Champiat S, Danlos FX, et al
    Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
    Eur J Cancer. 2017;75:308-309.

    March 2017
  153. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Abstract available

  154. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Abstract available

    February 2017
  155. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    PubMed     Abstract available

  156. SCHAFFAR R, Rachet B, Belot A, Woods LM, et al
    Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.
    Eur J Cancer. 2017;72:78-83.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.